NCT07103382View on ClinicalTrials.gov

Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 26, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Obesity
Interventions
DIETARY_SUPPLEMENT

Attapulgite

Participants were administered daily attapulgite (2.5 g) for a duration of 12 weeks.

DIETARY_SUPPLEMENT

Placebo

Participants were administered daily maltodextrin (2.5 g) for a duration of 12 weeks.

Trial Locations (1)

410011

RECRUITING

Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha

All Listed Sponsors
lead

Second Xiangya Hospital of Central South University

OTHER

NCT07103382 - Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial | Biotech Hunter | Biotech Hunter